Maria Sundvall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Sundvall has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Antti Kukkula
Cancer Research Unit, Institute of Biomedicine, and FICAN West Cancer Center Laboratory, University of Turku, and Turku University Hospital
5 shared publications- Verneri Virtanen
Cancer Research Unit, Institute of Biomedicine, and FICAN West Cancer Center Laboratory, University of Turku, and Turku University Hospital
5 shared publications - Heikki Minn
Department of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland.
4 shared publications - Anniina Hyväkkä
Department of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland
3 shared publications - Carlos Rogerio Figueiredo
Medical Immune Oncology Research Group (MIORG), Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland
3 shared publications - Ilkka Paatero
Turku Bioscience Centre, University of Turku and Abo Akademi University
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (4) , e70153
Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune‐Associated Biomarkers of Anti‐ PD1 Response in Metastatic Melanoma
Resistance to anti‐PD1 therapy remains a major challenge in metastatic melanoma, despite long‐term benefit in some patients. Since a functional dendritic cell (DC)‐CD8 + T cell axis is essential for anti‐PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC‐CD8 + T cell axis in melanoma, evaluating their associations with anti‐PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre‐treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker‐associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non‐responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment‐ and site‐specific. Among them, FAM57A , GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45 + immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K‐AKT‐mTORC1/MAPK signalling, especially upon co‐expression. Together, these results identify FAM57A , GSTA4 and KCTD1 as emerging immune‐associated biomarkers linked to established resistance‐associated immune states and poor prognosis in metastatic melanoma.
- 21 October 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (4) , e70153
Open AccessSpatial Transcriptomic and Proteomic Analysis Identifies Novel Immune‐Associated Biomarkers of Anti‐ PD1 Response in Metastatic Melanoma
Resistance to anti‐PD1 therapy remains a major challenge in metastatic melanoma, despite long‐term benefit in some patients. Since a functional dendritic cell (DC)‐CD8 + T cell axis is essential for anti‐PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC‐CD8 + T cell axis in melanoma, evaluating their associations with anti‐PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre‐treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker‐associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non‐responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment‐ and site‐specific. Among them, FAM57A , GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45 + immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K‐AKT‐mTORC1/MAPK signalling, especially upon co‐expression. Together, these results identify FAM57A , GSTA4 and KCTD1 as emerging immune‐associated biomarkers linked to established resistance‐associated immune states and poor prognosis in metastatic melanoma.
- Open Access
SUMOylation is a Therapeutic Vulnerability in High-risk Neuroblastoma
Neuroblastoma (NB) is one of the most common solid malignancies in children, and high-risk patients have poor prognosis, underscoring the need for novel therapeutic agents. The small ubiquitin-like modifier (SUMO) is a reversible post-translational modification that regulates various protein functions, and the first-in-class SUMOylation inhibitor TAK-981 (subasumstat) is currently in clinical trials in adult cancer patients. However, the role of SUMOylation in NB pathogenesis remains poorly characterized. We show that SUMOylation-catalyzing enzymes, SAE1, SAE2, and UBE2I, are highly expressed in malignant neuroendocrine cells, and their expression correlate with poor survival in NB patients and associate with advanced stage, MYCN amplifications, and downregulation of late differentiation markers. The peripheral nervous system lineage and NB cell lines are highly sensitive to the CRISPR knockout of SAE1 and SAE2, suggesting SUMOylation as promising therapeutic target in NB. Accordingly, TAK-981-mediated inhibition of SUMOylation reduces growth of NB cells in both in vitro and in vivo models through induction of apoptosis and perturbation of differentiation-associated pathways. Sensitivity to SUMOylation inhibition is greatest in NB cells with low expression of favorable late neuroblast markers and is independent of MYCN amplification status. Moreover, TAK-981 is effective in combination with differentiation-inducing all-trans retinoic acid and the DNA methyltransferase inhibitor decitabine. Mechanistically, combination of TAK-981 and retinoic acid potently downregulates retinoic acid receptor alpha (RARα) expression, whereas inhibition of SUMOylation combined with decitabine induces a strong accumulation of DNA damage. Taken together, these findings establish SUMO pathway components as potential prognostic markers and SUMOylation as a therapeutic vulnerability in high-risk NB.
Open AccessSUMOylation is a Therapeutic Vulnerability in High-risk Neuroblastoma
Neuroblastoma (NB) is one of the most common solid malignancies in children, and high-risk patients have poor prognosis, underscoring the need for novel therapeutic agents. The small ubiquitin-like modifier (SUMO) is a reversible post-translational modification that regulates various protein functions, and the first-in-class SUMOylation inhibitor TAK-981 (subasumstat) is currently in clinical trials in adult cancer patients. However, the role of SUMOylation in NB pathogenesis remains poorly characterized. We show that SUMOylation-catalyzing enzymes, SAE1, SAE2, and UBE2I, are highly expressed in malignant neuroendocrine cells, and their expression correlate with poor survival in NB patients and associate with advanced stage, MYCN amplifications, and downregulation of late differentiation markers. The peripheral nervous system lineage and NB cell lines are highly sensitive to the CRISPR knockout of SAE1 and SAE2, suggesting SUMOylation as promising therapeutic target in NB. Accordingly, TAK-981-mediated inhibition of SUMOylation reduces growth of NB cells in both in vitro and in vivo models through induction of apoptosis and perturbation of differentiation-associated pathways. Sensitivity to SUMOylation inhibition is greatest in NB cells with low expression of favorable late neuroblast markers and is independent of MYCN amplification status. Moreover, TAK-981 is effective in combination with differentiation-inducing all-trans retinoic acid and the DNA methyltransferase inhibitor decitabine. Mechanistically, combination of TAK-981 and retinoic acid potently downregulates retinoic acid receptor alpha (RARα) expression, whereas inhibition of SUMOylation combined with decitabine induces a strong accumulation of DNA damage. Taken together, these findings establish SUMO pathway components as potential prognostic markers and SUMOylation as a therapeutic vulnerability in high-risk NB.
- Open Access
- 31 July 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 202, 119803
Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma
- 31 July 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 202, 119803
Open AccessModelling targeted therapy efficacy in NRAS mutant conjunctival melanoma
- Open Access
- 31 July 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (8)
Nuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma
Objectives: To evaluate nuclear promyelocytic leukaemia protein (PML) expression as a prognostic biomarker in localised clear cell renal cell carcinoma (ccRCC), aiming to improve postoperative risk stratification. Materials and methods: Two independent retrospective cohorts of patients undergoing surgery for localised ccRCC were analysed: an exploratory cohort ( n = 191; Turku University Hospital) and a validation cohort ( n = 173; Helsinki University Hospital). Patients underwent surgery between 2005 and 2014 and 2006–2013, respectively. Tissue microarrays from primary tumours were immunohistochemically stained and assessed for nuclear PML expression using both visual scoring and QuPath‐assisted image analysis. Clinical data at the time of surgery and follow‐up data were collected, with a median follow‐up of 8 years in the exploratory cohort and 9 years in the validation cohort. Associations between nuclear PML expression and recurrence‐free survival (RFS), cancer‐specific survival (CSS), overall survival (OS) and diagnostic histopathological characteristics were evaluated. Results: High nuclear PML expression was associated with improved RFS ( p = 0.022) and CSS ( p = 0.027) in the exploratory cohort, with similar findings in the validation cohort in univariable analyses (both p < 0.0001). In the validation cohort, high nuclear PML expression remained independently associated with improved RFS (HR 0.38, 95% CI 0.21–0.70; p = 0.002), CSS (HR 0.30, 95% CI 0.13–0.68; p = 0.004) and OS (HR 0.34, 95% CI 0.18–0.68; p = 0.002) after adjustment for established histopathological risk factors in multivariable analyses. Conclusions: Nuclear PML expression is associated with favourable outcomes in localised ccRCC and may provide additional prognostic information. Independent validation and mechanistic studies are warranted.
- 31 July 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (8)
Open AccessNuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma
Objectives: To evaluate nuclear promyelocytic leukaemia protein (PML) expression as a prognostic biomarker in localised clear cell renal cell carcinoma (ccRCC), aiming to improve postoperative risk stratification. Materials and methods: Two independent retrospective cohorts of patients undergoing surgery for localised ccRCC were analysed: an exploratory cohort ( n = 191; Turku University Hospital) and a validation cohort ( n = 173; Helsinki University Hospital). Patients underwent surgery between 2005 and 2014 and 2006–2013, respectively. Tissue microarrays from primary tumours were immunohistochemically stained and assessed for nuclear PML expression using both visual scoring and QuPath‐assisted image analysis. Clinical data at the time of surgery and follow‐up data were collected, with a median follow‐up of 8 years in the exploratory cohort and 9 years in the validation cohort. Associations between nuclear PML expression and recurrence‐free survival (RFS), cancer‐specific survival (CSS), overall survival (OS) and diagnostic histopathological characteristics were evaluated. Results: High nuclear PML expression was associated with improved RFS ( p = 0.022) and CSS ( p = 0.027) in the exploratory cohort, with similar findings in the validation cohort in univariable analyses (both p < 0.0001). In the validation cohort, high nuclear PML expression remained independently associated with improved RFS (HR 0.38, 95% CI 0.21–0.70; p = 0.002), CSS (HR 0.30, 95% CI 0.13–0.68; p = 0.004) and OS (HR 0.34, 95% CI 0.18–0.68; p = 0.002) after adjustment for established histopathological risk factors in multivariable analyses. Conclusions: Nuclear PML expression is associated with favourable outcomes in localised ccRCC and may provide additional prognostic information. Independent validation and mechanistic studies are warranted.
- Open Access
- 23 July 2026
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 31
Association between brown adipose tissue activity and clinical outcomes in melanoma: a retrospective PET/CT analysis
- 23 July 2026
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 31
Open AccessAssociation between brown adipose tissue activity and clinical outcomes in melanoma: a retrospective PET/CT analysis
- Open Access
- 26 June 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (12) , 6837-6848
Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer
Purpose: To compare prostate-specific membrane antigen (PSMA) and fibroblast activation-protein inhibitor (FAPI) targeted PET/CT imaging to assess possible theranostic combination strategies of both tracers in metastatic prostate cancer (mPC). Methods: This prospective study enrolled patients with mPC who underwent long-axial field-of-view whole-body PET/CT with 18 F-DCFPyL and 18 F-FAPI-74 within two weeks. Fifteen patients had hormone sensitive (mHSPC) and 24 castration-resistant (mCRPC) disease. Scans were reviewed according to predefined criteria, with up to five metastases per anatomical region evaluated. Lesions were categorized in four groups as skeletal, pelvic nodal, extrapelvic nodal, or visceral. SUVmax and volumetric parameters were measured for each lesion and at the patient level. Results: A total of 1365 lesions were identified in 39 patients. 18 F-DCFPyL PET/CT detected 1351 lesions (99%). In contrast, 18 F–FAPI-74 identified only 788 (58%) lesions in the PSMA-guided analysis and 523 (38%) lesions in the independent analysis. Median lesion SUVmax was higher for PSMA (24) than for FAPI (5.4) (p < 0.001). Visceral metastases constituted 3% of lesions with both tracers and tended to be more often FAPI-avid (64%) compared to other lesion groups. Only 14 (1%) of lesions were FAPI-positive and PSMA-negative. In whole-tumor burden analysis, median tracer-positive tumor volume on 18 F-DCFPyL PET/CT was 85 mL and on 18 F-FAPI-74 PET/CT only 10 mL (p < 0.001). Conclusion: In mPC, PSMA PET/CT remains the preferred molecular imaging method. Our findings suggest only a limited role of FAPI radioligand therapy. FAPI theranostics should focus on patients with visceral metastases and specific histological subtypes beyond acinar adenocarcinoma. Clinical Trial Registration: EudraCT: 2022–003788-13. Registered 21 September 2023
- 26 June 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (12) , 6837-6848
Open AccessComparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer
Purpose: To compare prostate-specific membrane antigen (PSMA) and fibroblast activation-protein inhibitor (FAPI) targeted PET/CT imaging to assess possible theranostic combination strategies of both tracers in metastatic prostate cancer (mPC). Methods: This prospective study enrolled patients with mPC who underwent long-axial field-of-view whole-body PET/CT with 18 F-DCFPyL and 18 F-FAPI-74 within two weeks. Fifteen patients had hormone sensitive (mHSPC) and 24 castration-resistant (mCRPC) disease. Scans were reviewed according to predefined criteria, with up to five metastases per anatomical region evaluated. Lesions were categorized in four groups as skeletal, pelvic nodal, extrapelvic nodal, or visceral. SUVmax and volumetric parameters were measured for each lesion and at the patient level. Results: A total of 1365 lesions were identified in 39 patients. 18 F-DCFPyL PET/CT detected 1351 lesions (99%). In contrast, 18 F–FAPI-74 identified only 788 (58%) lesions in the PSMA-guided analysis and 523 (38%) lesions in the independent analysis. Median lesion SUVmax was higher for PSMA (24) than for FAPI (5.4) (p < 0.001). Visceral metastases constituted 3% of lesions with both tracers and tended to be more often FAPI-avid (64%) compared to other lesion groups. Only 14 (1%) of lesions were FAPI-positive and PSMA-negative. In whole-tumor burden analysis, median tracer-positive tumor volume on 18 F-DCFPyL PET/CT was 85 mL and on 18 F-FAPI-74 PET/CT only 10 mL (p < 0.001). Conclusion: In mPC, PSMA PET/CT remains the preferred molecular imaging method. Our findings suggest only a limited role of FAPI radioligand therapy. FAPI theranostics should focus on patients with visceral metastases and specific histological subtypes beyond acinar adenocarcinoma. Clinical Trial Registration: EudraCT: 2022–003788-13. Registered 21 September 2023
- Open Access
- 6 October 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (4) , 385-398
Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer
Lethal prostate cancer (PCa) is a genetically heterogeneous disease characterized by evolving androgen receptor (AR) signaling, eventually culminating in castration resistance. The tumor suppressor gene BRCA1 has multiple functions that include secondary processes cooperating with its main function as a caretaker of genomic integrity. BRCA1 is often mutated in breast and ovarian cancer, but BRCA1 mutations are also associated with PCa, although they are less frequently observed. Most PCa patients do not, however, carry BRCA1 mutations, and interestingly, it has been shown that BRCA1 expression is enriched in castration‐resistant PCa. In this study we elucidated the prostate tissue‐specific role of the BRCA1 protein. Although the regulation of DNA damage response genes has been studied in PCa, comprehensive analyses of BRCA1 regulation in the context of androgen signaling are lacking. Our results indicate that BRCA1 is dynamically regulated by AR signaling and that activation of AR via its natural ligand, dihydrotestosterone, represses BRCA1 expression. Our analyses both in vitro and of patient samples and mouse xenografts showed that BRCA1 expression was induced and sustained after androgen deprivation. Moreover, we observed that oxidative stress–related pathways were regulated by BRCA1 in PCa cells and that androgen deprivation therapy–induced activation of BRCA1 supported the function of NRF2, the master regulator of antioxidant defense, and a known interactor of BRCA1. Impaired NRF2 activity, in the absence of BRCA1, decreased growth in a 3D environment. Our findings shed light on the functional role of BRCA1 protein in PCa and suggest that BRCA1 is regulated by the evolving AR signaling state during PCa progression. Thus, AR‐mediated suppression of BRCA1 accumulates oncogenic alterations in the early phases of PCa tumor progression and safeguards from excessive reactive oxygen species (ROS) when upregulated during androgen deprivation therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 6 October 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (4) , 385-398
Open AccessAndrogen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer
Lethal prostate cancer (PCa) is a genetically heterogeneous disease characterized by evolving androgen receptor (AR) signaling, eventually culminating in castration resistance. The tumor suppressor gene BRCA1 has multiple functions that include secondary processes cooperating with its main function as a caretaker of genomic integrity. BRCA1 is often mutated in breast and ovarian cancer, but BRCA1 mutations are also associated with PCa, although they are less frequently observed. Most PCa patients do not, however, carry BRCA1 mutations, and interestingly, it has been shown that BRCA1 expression is enriched in castration‐resistant PCa. In this study we elucidated the prostate tissue‐specific role of the BRCA1 protein. Although the regulation of DNA damage response genes has been studied in PCa, comprehensive analyses of BRCA1 regulation in the context of androgen signaling are lacking. Our results indicate that BRCA1 is dynamically regulated by AR signaling and that activation of AR via its natural ligand, dihydrotestosterone, represses BRCA1 expression. Our analyses both in vitro and of patient samples and mouse xenografts showed that BRCA1 expression was induced and sustained after androgen deprivation. Moreover, we observed that oxidative stress–related pathways were regulated by BRCA1 in PCa cells and that androgen deprivation therapy–induced activation of BRCA1 supported the function of NRF2, the master regulator of antioxidant defense, and a known interactor of BRCA1. Impaired NRF2 activity, in the absence of BRCA1, decreased growth in a 3D environment. Our findings shed light on the functional role of BRCA1 protein in PCa and suggest that BRCA1 is regulated by the evolving AR signaling state during PCa progression. Thus, AR‐mediated suppression of BRCA1 accumulates oncogenic alterations in the early phases of PCa tumor progression and safeguards from excessive reactive oxygen species (ROS) when upregulated during androgen deprivation therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- Open Access
- 8 July 2025
- Published by Springer Nature in Research Square
Novel Anti-PD1 Predictive Signature and Functional Dendritic-Cell Biomarkers in Melanoma Identified with Systems Immunology
Despite the success of anti-PD1 immunotherapy in melanoma, identifying biomarkers for response prediction and rational treatment combinations remains a major challenge. Effective dendritic cell (DC):CD8+ T cell crosstalk in the tumor microenvironment enhances anti-PD1 responses; however, no predictive signatures reflect this interaction. To address this, we developed a systems immunology approach based on DC:CD8+ T cell crosstalk reference biomarkers CD74 and CD8A, leading to the discovery of a 15-gene immune signature called PRIME, incorporated into a logistic regression framework for anti-PD1 response prediction in melanoma. PRIME outperforms previous signatures, especially in tumors with high CD8+ T cells, reflecting a functional immune response. Integrating clinical, molecular, spatial, and single-cell profiling identified SLAMF7 and TYMP as new functional biomarker candidates in DCs. Mechanistic studies revealed that these biomarkers regulate antigen processing and presentation in DCs. Our study demonstrates a new strategy for predicting anti-PD1 responses in melanoma, revealing biomarkers with functional roles that may inform future therapeutic development.
- 8 July 2025
- Published by Springer Nature in Research Square
Open AccessNovel Anti-PD1 Predictive Signature and Functional Dendritic-Cell Biomarkers in Melanoma Identified with Systems Immunology
Despite the success of anti-PD1 immunotherapy in melanoma, identifying biomarkers for response prediction and rational treatment combinations remains a major challenge. Effective dendritic cell (DC):CD8+ T cell crosstalk in the tumor microenvironment enhances anti-PD1 responses; however, no predictive signatures reflect this interaction. To address this, we developed a systems immunology approach based on DC:CD8+ T cell crosstalk reference biomarkers CD74 and CD8A, leading to the discovery of a 15-gene immune signature called PRIME, incorporated into a logistic regression framework for anti-PD1 response prediction in melanoma. PRIME outperforms previous signatures, especially in tumors with high CD8+ T cells, reflecting a functional immune response. Integrating clinical, molecular, spatial, and single-cell profiling identified SLAMF7 and TYMP as new functional biomarker candidates in DCs. Mechanistic studies revealed that these biomarkers regulate antigen processing and presentation in DCs. Our study demonstrates a new strategy for predicting anti-PD1 responses in melanoma, revealing biomarkers with functional roles that may inform future therapeutic development.
- Open Access
- 29 April 2025
- Published by ScienceOpen
Patient-derived lymphoma organoids and repurposed drugs: novel solutions for improved B cell lymphoma treatment
B cell lymphomas (BCL) are a heterogenous group of hematologic malignancies, with over 70 identified subtypes. Current first line treatment for all subtypes is rituximab and chemotherapy regimen (R-CHOP); of the treated patients, up to 40-60% relapse or have refractory disease, with typically higher mortality rates. Therefore, more efficient treatment, but also improved ex vivo research models are needed to study the treatment response and resistance. To overcome the expensive and time-consuming process of drug discovery and development, we aim to combat the lymphoma heterogeneity with repurposed drugs, especially focusing on cationic amphiphilic drugs (CADs) that damage cancer cell lysosomes. Lysosomes are central organelles in nutrient sensing and cellular metabolism. Malignant transformation rewires cellular metabolism to boost growth. In turn, cancer cells increase lysosomal production and activity to meet the metabolic needs. Our current results indicate that targeting the reported cancer cell lysosomal ‘weakness’ with repurposed CADs Ebastine and Penfluridol prevents pro-survival cell signaling, and suppresses long-term tumor outgrowth in B lymphoma cell lines, patient blood B cells, and in patient lymph node-derived organoids. We have developed a novel patient-derived lymphoma organoid model as an ex vivo drug assay platform from patients’ own cancer tissue. With combining the lymphoma organoid model and repurposed drugs, this study provides a simpler and cost-effective, yet translationally relevant clinical solution for personalized medicine and improved treatment of BCL patients.
- 29 April 2025
- Published by ScienceOpen
Open AccessPatient-derived lymphoma organoids and repurposed drugs: novel solutions for improved B cell lymphoma treatment
B cell lymphomas (BCL) are a heterogenous group of hematologic malignancies, with over 70 identified subtypes. Current first line treatment for all subtypes is rituximab and chemotherapy regimen (R-CHOP); of the treated patients, up to 40-60% relapse or have refractory disease, with typically higher mortality rates. Therefore, more efficient treatment, but also improved ex vivo research models are needed to study the treatment response and resistance. To overcome the expensive and time-consuming process of drug discovery and development, we aim to combat the lymphoma heterogeneity with repurposed drugs, especially focusing on cationic amphiphilic drugs (CADs) that damage cancer cell lysosomes. Lysosomes are central organelles in nutrient sensing and cellular metabolism. Malignant transformation rewires cellular metabolism to boost growth. In turn, cancer cells increase lysosomal production and activity to meet the metabolic needs. Our current results indicate that targeting the reported cancer cell lysosomal ‘weakness’ with repurposed CADs Ebastine and Penfluridol prevents pro-survival cell signaling, and suppresses long-term tumor outgrowth in B lymphoma cell lines, patient blood B cells, and in patient lymph node-derived organoids. We have developed a novel patient-derived lymphoma organoid model as an ex vivo drug assay platform from patients’ own cancer tissue. With combining the lymphoma organoid model and repurposed drugs, this study provides a simpler and cost-effective, yet translationally relevant clinical solution for personalized medicine and improved treatment of BCL patients.
- Open Access
- 2 November 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (21) , e70371
xCT as a Predictor for Survival in a Population‐Based Cohort of Head and Neck Squamous Cell Carcinoma
Background: xCT, also known as SLC7A11 (solute carrier Family 7 Member 11), is a cystine/glutamate antiporter protein that mediates regulated cell death and antioxidant defense. The aim of this study was to investigate the effect of xCT on the outcome of patients diagnosed with new head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective cohort study utilized a population‐based dataset, comprising all patients ( n = 1033) diagnosed with new HNSCC during 2005–2015 in a population of 697,000 people. All patients ( n = 585) with a tumor tissue sample available for immunohistochemical (IHC) staining were included. The follow‐up rates were 97% and 81% at 3 and 5 years, respectively. Also, the specificity of the anti‐xCT antibody was validated. Results: The expression level and prognostic significance of xCT were strongly dependent on tumor location. In oropharyngeal squamous cell carcinoma (OPSCC) patients, xCT expression was a significant prognostic factor for 5‐year overall survival (OAS) (HR: 2.71; 95% CI 1.67–4.39; p < 0.001), disease‐specific survival (DSS) (HR: 2.58; 95% CI 1.47–4.54; p = 0.001), and disease‐free survival (DFS) (HR: 2.69; 95% CI 1.55–4.64; p < 0.001). Five‐year survival rates for OPSCC patients with high and low levels of xCT were OAS 34% versus 62%; DSS 51% versus 73%; DFS 43% versus 73%, respectively. According to a multivariate model adjusted for age, T‐class, nodal positivity, and tobacco consumption, xCT was an independent prognostic factor for 3‐year survival, in which it outperformed p16 IHC. Similar associations were not observed in squamous cell carcinomas of oral cavity or larynx. Regarding treatment modalities, xCT was most predictive in HNSCC patients who received radiotherapy. Conclusions: High xCT expression was associated with poor prognosis in OPSCC. Our findings suggest that joint analysis of xCT and p16 may add significant value in OPSCC treatment stratification.
- 2 November 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (21) , e70371
Open AccessxCT as a Predictor for Survival in a Population‐Based Cohort of Head and Neck Squamous Cell Carcinoma
Background: xCT, also known as SLC7A11 (solute carrier Family 7 Member 11), is a cystine/glutamate antiporter protein that mediates regulated cell death and antioxidant defense. The aim of this study was to investigate the effect of xCT on the outcome of patients diagnosed with new head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective cohort study utilized a population‐based dataset, comprising all patients ( n = 1033) diagnosed with new HNSCC during 2005–2015 in a population of 697,000 people. All patients ( n = 585) with a tumor tissue sample available for immunohistochemical (IHC) staining were included. The follow‐up rates were 97% and 81% at 3 and 5 years, respectively. Also, the specificity of the anti‐xCT antibody was validated. Results: The expression level and prognostic significance of xCT were strongly dependent on tumor location. In oropharyngeal squamous cell carcinoma (OPSCC) patients, xCT expression was a significant prognostic factor for 5‐year overall survival (OAS) (HR: 2.71; 95% CI 1.67–4.39; p < 0.001), disease‐specific survival (DSS) (HR: 2.58; 95% CI 1.47–4.54; p = 0.001), and disease‐free survival (DFS) (HR: 2.69; 95% CI 1.55–4.64; p < 0.001). Five‐year survival rates for OPSCC patients with high and low levels of xCT were OAS 34% versus 62%; DSS 51% versus 73%; DFS 43% versus 73%, respectively. According to a multivariate model adjusted for age, T‐class, nodal positivity, and tobacco consumption, xCT was an independent prognostic factor for 3‐year survival, in which it outperformed p16 IHC. Similar associations were not observed in squamous cell carcinomas of oral cavity or larynx. Regarding treatment modalities, xCT was most predictive in HNSCC patients who received radiotherapy. Conclusions: High xCT expression was associated with poor prognosis in OPSCC. Our findings suggest that joint analysis of xCT and p16 may add significant value in OPSCC treatment stratification.